UnknownPhase 3

Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

Qatar12 participantsStarted 2018-09-20

Plain-language summary

A total of 12 subjects will be recruited for participation in this study. 6 subjects will receive re-infusion of autologous blood, and 6 subjects (anemic patients) will receive a homologous transfusion.

Who can participate

Age range20 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * both genders, * age 20-50 years and * preferably physically active but no elite athletes subjected to Anti-Doping testing. Exclusion Criteria: * vulnerable subjects * not willing to participate * not signing the ICF * patients with end-organ failure

What they're measuring

Donor DNA (# of loci with triplets or quadruplets):

Timeframe: 12 months

Cellular Microparticles (10^3/uL):

Timeframe: 12 months

Trial details

NCT IDNCT03548766

SponsorHamad Medical Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-12

Contact for this trial

Sven C Voss

0097455481955 svoss@adlqatar.qa

View on ClinicalTrials.gov More Blood Disease trials